Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
The Conversation logo

“One more question,” is now a regular parting shot from the son or daughter of a patient I have just diagnosed with dementia. It is dropped in just as they are about to leave – almost an afterthought.

Typically, we have spent the last hour painting a picture of the road ahead for the family: the trauma of shifting from the role of a grownup child to one of a carer, a succession of losses, and ultimately the fading of the person they had once known.

In the past, the stunned family may have silently filed out, deep in thought. But now we tend to stand by the door, opening a new conversation. “What can I do to not get this?”

It is difficult to overstate the opportunity for dementia research that is contained within this repeated question. Researchers have long recognised the value of treating dementia in its “pre-clinical” phase. But it is difficult to conduct clinical studies in people with few or no symptoms. To do so, you need reliable tests to detect pre-clinical dementia and you need to monitor the effects of the treatments being tested.

Read the full article on The Conversation website, written by Ivan Koychev, Senior Clinical Researcher, Department of Psychiatry.

Oxford is a subscribing member of The ConversationFind out how you can write for The Conversation.

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.